secretagogue is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-03. Numbers and descriptions here follow the published literature rather than marketing material.
In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.
Research peptides such as ipamorelin are commonly supplied as lyophilized powder and characterized by analytical certificates. Reversed-phase high-performance liquid chromatography is used to estimate purity by ultraviolet absorbance, while mass spectrometry confirms molecular identity and detects sequence-related impurities. Counterion content, water content, and residual synthesis reagents can affect the reported mass balance. A certificate of analysis may list a purity percentage, but that number depends on the analytical method and the definition of impurity peaks. Independent verification is often recommended because research supply chains vary in quality control practices.
杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子，其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱，因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件，不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照，但其自身赋值同样需要可追溯来源。
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility class | Soluble in water and aqueous buffers | Solubility can depend on pH and salt form |
| Typical storage temperature | −20 °C or lower, desiccated | Protect from light and moisture |
| Typical analytical method | RP-HPLC with UV detection; LC-MS | Identity and purity assessment |
| Common salt form | Acetate salt | Frequently used in research supply |
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
在 GHS 家族中，早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放，并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性，对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同，而完整的分子解释仍有待补充。需要区分的是，选择性是研究观察中的相对程度，并非绝对界限。
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
Ipamorelin (INN; development code NNC 26-0161) is a peptide selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS) and a growth hormone secretagogue. It is a pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 that was derived from GHRP-1. Ipamorelin significantly increases plasma growth hormone (GH) levels in both animals and humans. In addition, ipamorelin stimulates body weight gain in animals. In rats, ipamorelin has also been reported to induce longitudinal bone growth. Like pralmorelin and GHRP-6, ipamorelin does not affect prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), or thyroid-stimulating hormone (TSH) levels. However, unlike pralmorelin (GHRP-2) and GHRP-6, but similarly to growth hormone-releasing hormone (GHRH), ipamorelin does not stimulate the secretion of adrenocorticotropic hormone (ACTH), or cortisol, and is highly selective for inducing the secretion only of GH. Ipamorelin was originally developed by Novo Nordisk, and was investigated in phase II clinical trials by Helsinn Therapeutics for the treatment of postoperative ileus, but was discontinued due to lack of efficacy. Ipamorelin has been used by athletes as a performance-enhancing drug. Currently, Ipamorelin is commonly marketed as a research peptide rather than as an approved pharmaceutical drug.
Diffuse cerebral hypoxia – A mild to moderate impairment of brain function due to low oxygen levels in the blood. Focal cerebral ischemia – A stroke occurring in a localized area that can either be acute or transient. This may be due to a variety of medical conditions such as an aneurysm that causes a hemorrhagic stroke, or an occlusion occurring in the affected blood vessels due to a thrombus (thrombotic stroke) or embolus (embolic stroke). Focal cerebral ischemia constitutes a large majority of the clinical cases in stroke pathology with the infarct usually occurring in the middle cerebral artery (MCA). Global cerebral ischemia – A complete stoppage of blood flow to the brain. Cerebral infarction – A "stroke", caused by complete oxygen deprivation due to an interference in cerebral blood flow which affects multiple areas of the brain. Cerebral hypoxia can also be classified by the cause of the reduced brain oxygen:
==== 2600–2699 ==== Greater Manchester Ambulance Service National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2600) Lancashire Ambulance Service National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2601) Tameside and Glossop Acute Services National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2602) Darlington Memorial Hospital National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2603) Bolton Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2604) Priority Healthcare Wearside National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2605) Community Health Care Service (North Derbyshire) National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2606) Wirral Community Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2607) North Lakeland Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2608) North Downs Community Health National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2609) South Durham Health Care National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2610) Salford Community Health Care National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2611) Community Health Care: North Durham National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2612) Kingston and District Community National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2613) North Durham Acute Hospitals National Health Service Trust (Establishment) Order 1993 (S.I.
Mid-Atlantic Ridge province, East Scotia Ridge province, northern East Pacific Rise province, central East Pacific Rise province, southern East Pacific Rise province, south of the Easter Microplate, Indian Ocean province, four provinces in the western Pacific and many more.
Sources: en.wikipedia.org
== Epidemiology == The current estimated global incidence annually is 20,000 to 50,000 people, though a large number of cases are believed to go unreported. Due to the limited habitats of ciguatoxin-producing microorganisms, ciguatera is common only in subtropical and tropical waters, particularly the Pacific and Caribbean, and usually is associated with fish caught in tropical reef waters. Exportation of reef fish, as well as tourism, often account for cases that develop in other regions. Ciguatoxin is found in over 400 species of reef fish. Avoiding consumption of all reef fish is the only sure way to avoid exposure. Imported fish served in restaurants may contain the toxin and produce illness which often goes unexplained by physicians unfamiliar with the symptoms of a tropical toxin. Ciguatoxin can also occur in farm-raised salmon. Furthermore, species substitution, labeling a reef fish as a non-reef fish at restaurants and retail, can complicate efforts by consumers to avoid ciguatera.
== Other business activity == Upon leaving Pepsi, Bello formed JoNa Ventures, a family investment vehicle that included among other endeavors investment and active involvement in Firefighter Brands, Soup Kitchen International, Eye and PresbyopiaTherapies and Beso Del Sol Sangria. With former NFL associates Bruce Burke and Peter French, Bello formed Firefighter Brands, a social enterprise intended to benefit local firefighting units with revenues generated from the sale of Firefighter Branded coffee, chips, chili's, trail mixes and energy drinks. The project was supported by a group of well to do and high-profile community minded investors but ultimately failed due to lack of cohesive co-operation among various firefighting entities. In 2005, Bello invested in and became chairman of Soup Kitchen International, a company he helped found that markets soups created by Al Yeganeh, the New York-based soup chef made famous as the "Soup Nazi" on the popular Seinfeld TV show, for retail stores, and developed franchised restaurants. In 2006 Bello became a general partner of Sherbrooke Capital, a venture capital firm that provides growth capital to early-stage health and wellness companies that led the $6.35 million equity-financing round for IZZE in early 2005. In the spring of 2006, Bello was appointed Chairman of the Board of the IZZE Beverage Company, a maker of sparkling juices. Izze was subsequently sold to PepsiCo for an undisclosed sum. Currently, Bello is in partnership with his college roommate and fraternity brother Dr. Lee Nordan serving as chairman of Eye Therapies.
An alternating copolymer has regular alternating A and B units, and is often described by the formula: -A-B-A-B-A-B-A-B-A-B-, or -(-A-B-)n-. The molar ratio of each monomer in the polymer is normally close to one, which happens when the reactivity ratios r1 and r2 are close to zero, as can be seen from the Mayo–Lewis equation. For example, in the free-radical copolymerization of styrene maleic anhydride copolymer, r1 = 0.097 and r2 = 0.001, so that most chains ending in styrene add a maleic anhydride unit, and almost all chains ending in maleic anhydride add a styrene unit. This leads to a predominantly alternating structure. A step-growth copolymer -(-A-A-B-B-)n- formed by the condensation of two bifunctional monomers A–A and B–B is in principle a perfectly alternating copolymer of these two monomers, but is usually considered as a homopolymer of the dimeric repeat unit A-A-B-B. An example is nylon 66 with repeat unit -OC-( CH2)4-CO-NH-(CH2)6-NH-, formed from a dicarboxylic acid monomer and a diamine monomer.
Sources: en.wikipedia.org
==== Tolerance ==== Several hypotheses are given about how tolerance develops, including opioid receptor phosphorylation (which would change the receptor conformation), functional decoupling of receptors from G-proteins (leading to receptor desensitization), μ-opioid receptor internalization or receptor down-regulation (reducing the number of available receptors for morphine to act on), and upregulation of the cAMP pathway (a counterregulatory mechanism to opioid effects) (For a review of these processes, see Koch and Hollt).
=== Legal recognition of denturists === The 1919 Tasmanian Dental Act made a clear distinction between the role of a Dentist and the practice of denture making. For a patient that required dentures, a consultation by referral from a Dentist became normal procedure. Denturism – that is the field of dentures - was not recognised until more recent times. The Health Amendment Act (1933) was the first legal document that gave rise to the practice of Denturism in Canada. The Dental Mechanics Act of Alberta (1961) was the future update to this legislation allowing Denturists to begin work in the field. They were also known as "Dental Mechanics" or "Denture Therapists." This gave rise for the need for legal recognition of denturists in other countries. In the United States, the first legally recognised Denturists were found in Oregon, 1971. In 1974, denturists were first legally recognised and in 1978, Denture Therapists began practicing. The increasing rate of ill-fitting, misaligned, unstable and unsupportive dentures motivated three Denturists in 1956 to pursue international recognition. Rolf Pfenniger, Hannes Stiebler and Stephan Grabert formed the Internationale Arbeitsgemeinschaft der Zahnprothetiker. In English, this is the International Federation of Denturists. Denturists have campaigned for the right to practice independently in many states, with the argument that they can provide greater access and lower-cost prosthetic services. This argument has been disproved by examining other jurisdictions in the world which have both dentists and denturists.
=== Phase 2 === Cannabidiol (CBD; ATL5; RLS103) – cannabinoid receptor modulator and other actions Cannabidiol (CBD; Empower CBD) – cannabinoid receptor modulator and other actions ENX-102 (ENX102) — α2, α3, and α5 subunit-containing GABAA receptor positive allosteric modulator and nonbenzodiazepine FKW00GA (FKW-00GA; TGW-00AA; TGW00AA) – serotonin 5-HT1A receptor partial agonist and serotonin 5-HT2A receptor antagonist JNJ-42165279 (JNJ-5279) – fatty acid amide hydrolase (FAAH) inhibitor (R)-Midomafetamine ((R)-MDMA; R-MDMA; EMP-01) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2A, 5-HT2B, 5-HT2C receptor agonist, entactogen, and weak psychedelic hallucinogen Non-racemic MDMA (ALA-002; 70–80% (R)-MDMA, 20–30% (S)-MDMA) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2A, 5-HT2B, 5-HT2C receptor agonist, entactogen, and weak psychedelic hallucinogen NTX-1472 (RO-6953958) – vasopressin V1A receptor antagonist ONO-1110 – endocannabinoid synthesis regulator and indirect cannabinoid receptor modulator [3] [4] [5] Oxytocin (intranasal potentiated oxytocin; TI-001; TI-114; TNX-1900; TNX-2900) – oxytocin receptor agonist Vilazodone (Viibryd) – serotonin 5-HT1A receptor partial agonist and serotonin reuptake inhibitor
Sources: en.wikipedia.org
Purity is commonly estimated by reversed-phase high-performance liquid chromatography with ultraviolet detection. Mass spectrometry is used to confirm identity and to detect sequence-related impurities. Reported percentages depend on the method and the impurity threshold used.
Lyophilized powder is usually kept frozen, desiccated, and protected from light. Reconstituted solutions are often divided into aliquots and stored at very low temperature to limit freeze-thaw cycles. Specific conditions should follow the supplier's certificate of analysis and the assay requirements.
Much of the evidence comes from animal models and cell-based assays rather than large human trials. Small sample sizes, short follow-up, and differences in dosing or route make comparisons difficult. Questions about long-term effects and human relevance remain open.
肽键在 214 nm 附近有较强吸收，适合检测缺少芳香侧链的短肽。该波长的基线受流动相组成与梯度影响较大。因此流动相与梯度条件需要固定并完整记录。